A detailed history of Ifm Investors Pty LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ifm Investors Pty LTD holds 53,422 shares of VRTX stock, worth $27.6 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
53,422
Previous 53,487 0.12%
Holding current value
$27.6 Million
Previous $25.1 Million 0.9%
% of portfolio
0.24%
Previous 0.26%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$460.0 - $505.78 $29,900 - $32,875
-65 Reduced 0.12%
53,422 $24.8 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $406,165 - $502,038
1,034 Added 1.97%
53,487 $25.1 Million
Q1 2024

Apr 22, 2024

SELL
$407.69 - $446.08 $86,837 - $95,015
-213 Reduced 0.4%
52,453 $21.9 Million
Q4 2023

Jan 12, 2024

SELL
$343.0 - $410.68 $95,011 - $113,758
-277 Reduced 0.52%
52,666 $21.4 Million
Q3 2023

Oct 26, 2023

BUY
$338.18 - $362.46 $575,920 - $617,269
1,703 Added 3.32%
52,943 $18.4 Million
Q2 2023

Jul 27, 2023

BUY
$314.42 - $351.91 $1.29 Million - $1.44 Million
4,102 Added 8.7%
51,240 $18 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $403,036 - $459,771
1,423 Added 3.11%
47,138 $14.9 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $338,339 - $380,632
1,184 Added 2.66%
45,715 $13.2 Million
Q3 2022

Oct 12, 2022

BUY
$273.83 - $305.53 $164,571 - $183,623
601 Added 1.37%
44,531 $12.9 Million
Q2 2022

Jul 15, 2022

BUY
$234.96 - $292.55 $516,677 - $643,317
2,199 Added 5.27%
43,930 $12.4 Million
Q1 2022

Apr 13, 2022

BUY
$221.42 - $260.97 $1.67 Million - $1.97 Million
7,534 Added 22.03%
41,731 $10.9 Million
Q4 2021

Jan 18, 2022

SELL
$177.01 - $223.45 $71,335 - $90,050
-403 Reduced 1.16%
34,197 $7.51 Million
Q3 2021

Oct 13, 2021

BUY
$181.39 - $202.99 $362 - $405
2 Added 0.01%
34,600 $6.28 Million
Q2 2021

Jul 16, 2021

BUY
$187.49 - $221.1 $1.08 Million - $1.28 Million
5,776 Added 20.04%
34,598 $6.98 Million
Q1 2021

May 05, 2021

BUY
$207.02 - $241.31 $796,612 - $928,560
3,848 Added 15.41%
28,822 $6.19 Million
Q4 2020

Jan 13, 2021

BUY
$207.01 - $276.09 $620,408 - $827,441
2,997 Added 13.64%
24,974 $5.9 Million
Q3 2020

Oct 16, 2020

BUY
$255.65 - $303.1 $790,725 - $937,488
3,093 Added 16.38%
21,977 $5.98 Million
Q2 2020

Jul 13, 2020

SELL
$225.48 - $295.8 $1.49 Million - $1.95 Million
-6,591 Reduced 25.87%
18,884 $5.48 Million
Q1 2020

Apr 09, 2020

SELL
$199.77 - $247.81 $188,383 - $233,684
-943 Reduced 3.57%
25,475 $5.91 Million
Q4 2019

Jan 13, 2020

SELL
$166.71 - $223.91 $196,384 - $263,765
-1,178 Reduced 4.27%
26,418 $5.78 Million
Q3 2019

Nov 01, 2019

BUY
$166.23 - $187.09 $1.58 Million - $1.78 Million
9,502 Added 52.51%
27,596 $4.68 Million
Q2 2019

Jul 16, 2019

BUY
$164.61 - $190.37 $202,305 - $233,964
1,229 Added 7.29%
18,094 $3.32 Million
Q1 2019

Apr 18, 2019

BUY
$163.73 - $194.7 $356,931 - $424,446
2,180 Added 14.85%
16,865 $3.1 Million
Q4 2018

Jan 23, 2019

BUY
$151.91 - $192.21 $202,040 - $255,639
1,330 Added 9.96%
14,685 $2.43 Million
Q3 2018

Oct 22, 2018

BUY
$167.73 - $192.74 $327,744 - $376,613
1,954 Added 17.14%
13,355 $2.57 Million
Q2 2018

Jul 09, 2018

BUY
$145.72 - $169.96 $513,663 - $599,109
3,525 Added 44.76%
11,401 $1.94 Million
Q1 2018

May 11, 2018

BUY
$151.6 - $177.13 $126,282 - $147,549
833 Added 11.83%
7,876 $1.28 Million
Q4 2017

Jan 29, 2018

BUY
$137.28 - $155.55 $5,765 - $6,533
42 Added 0.6%
7,043 $1.06 Million
Q3 2017

Nov 16, 2017

BUY
$148.13 - $162.24 $29,774 - $32,610
201 Added 2.96%
7,001 $1.06 Million
Q2 2017

Nov 21, 2017

BUY
N/A
6,800 New
6,800 $876,000
Q2 2017

Aug 10, 2017

SELL
N/A
-4,989 Closed
0 $0
Q1 2017

Nov 21, 2017

BUY
N/A
4,989
4,989 $546,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ifm Investors Pty LTD Portfolio

Follow Ifm Investors Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifm Investors Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Ifm Investors Pty LTD with notifications on news.